FIELD: medicine, narcology.
SUBSTANCE: during the 1st d it is necessary to perform special seance and medicinal therapy by applying apparatuses for ultraviolet irradiation of blood of "Izolda" and "Nadezhda" type: system for blood transfusion should be connected with a sterile Janet's syringe of 150 ml capacity with pre-applied sterile solution of "Glugicir" containing 3.8% sodium citrate solution in the quantity that solution : blood ratio should correspond to 1:5. After washing the system one should puncture one of the peripheral veins of forearm, then blood should be slowly pumped up into the syringe to be similarly reinfused, the quantity of sampled blood corresponds to 1 ml/kg patient's body weight. Passing through irradiation chamber of 20 cm length blood is irradiated with blue light at power density being 0.16 mW/sq. cm; twice (at exfusion and reinfusion). At an average, the procedure lasts for 5-10 min depending upon patient's body weight. Medicinal therapy consists of: Sol. Pyracetami 20% - 5.0 ml i/m, once; Sol. Unitioli 5% - 5.0 ml i/m, once; Sol. Vitamini B-6 5% - 5.0 ml i/m, once; Pyrroxani 0.015 g thrice daily; bellataminal 0.001 g nocturnally. On the 2nd d it is necessary to perform special seance followed by that of hydrocolonotherapy upon apparatus for intestinal monitor purification. On the 3d d one should perform special monotherapy. After applying the above-mentioned course patient should be invited for repeated visit to control therapy conducted and perform prophylactic procedure 1 mo and 3 mo later (after the first course) to improve effect. The innovation enables to shorten therapy terms and decrease the number of complications considerably.
EFFECT: higher efficiency of therapy.
2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF ALCOHOLIC ABSTINENCE SYNDROME REDUCTION | 2006 |
|
RU2327474C1 |
METHOD OF REHABILITATION OF PATIENTS WITH ALCOHOLISM | 2009 |
|
RU2436573C2 |
METHOD FOR PREDICTING REMISSION DURATION IN ALCOHOL ADDICTED PATIENTS AT THE REMISSION DEVELOPMENT PERIOD | 2002 |
|
RU2238034C2 |
MEDICINAL AGENT FOR ETHYL ALCOHOL AND/OR NARCOTIC ADDICTION TREATMENT, PARMACEUTICAL COMPOSITION, ACTIVE INGREDIENT OF PHARMACEUTICAL COMPOSITION, METHOD OF ETHYL ALCOHOL AND/OR NARCOTIC ADDICTION TREATMENT FOR ALCOHOLICS' AND/OR NARCOTISTS' PSYCHOSOMATIC AND NEUROLOGICAL COMPLICATION TREATMENT | 2007 |
|
RU2327448C1 |
METHOD OF TREATING WITHDRAWAL SYNDROME IN ALCOHOLISM | 2019 |
|
RU2726465C1 |
METHOD OF TREATING ALCOHOLIC DEPENDENCE AND OPIUM ADDICTION 'UNIVERSAL PSYCHOPHARMACOLOGICAL NEUROPHYSIOLOGICAL BLOCK' | 2009 |
|
RU2444352C2 |
METHOD FOR OPTIMIZING THERAPY OF CLIMACTERIC SYNDROME | 2005 |
|
RU2302264C1 |
METHOD FOR ALLEVIATING COMPLICATED ABSTINENCE SYNDROME | 1992 |
|
RU2067442C1 |
METHOD OF RELIEVING ALCOHOL ABSTINENCE SYNDROME BY BLOCKADE OF BENZODIAZEPINE RECEPTORS | 2011 |
|
RU2468799C1 |
METHOD FOR PREDICTING THE DURATION OF THERAPEUTIC REMISSION IN PATIENTS WITH ALCOHOLISM | 2021 |
|
RU2756613C1 |
Authors
Dates
2005-10-27—Published
2004-04-29—Filed